Now more than ever, it is vitally important to understand how to integrate stakeholders’ perspectives early, and think about approval and reimbursement in parallel with innovation and R&D.

Understanding how value is created in this context is critical to effectively managing the discovery, development and commercialization process in a patient-centric ecosystem.  But in an increasingly constrained and complex environment, various challenges arise for all stakeholders. In particular:

• How are decisions made when value is not evident?
• How does a drug that goes beyond providing incremental improvements get developed and what are the relevant indicators
• How are designs conducted when standardization is limited?
• How does one understand and manage the various perspectives of value in a constantly shifting landscape?

Speakers:

• Edwin M. Kania, Jr., Managing Partner and Chairman, Flagship Ventures
• Tony Manning, PhD, Vice President, Research, Momenta Pharmaceuticals
• Kevin Sooben, PhD, Project Manager – Intelligent Pharmaceuticals (Digital Health), AstraZeneca

Moderator:

• Jeff Elton, PhD, Managing Director, Accenture Strategy

From the perspectives of their own organization and networks, our speakers will discuss value as it relates to the major phases from early discovery to clinical development, regulatory approval and other life cycle changes:

• Value at discovery and clinical stages
• Valuation  in the current marketplace
• Improving Value through Life Cycle management .

Please join the conversation as our panel of industry experts discuss key intersections of science & business in the life sciences value chain such as:

• Understanding the strategic & financial value of innovation:
  • How to achieve sustainable growth in the R&D pipeline through in/out licensing strategies
  • The role of capital markets in monetizing investment and facilitating innovation throughout the value chain
  • Advances and trends in the use of financial structuring in de-risking large R&D efforts
• Transformational versus incremental innovation and teh trade-offs:
  • Novel is often transformational but how risky is it? What are risk tolerances of the various stakeholders along the science/business divide?
  • Orphan disease and other niche strategies